(2S)-6-bromo-5-oxo-2-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hexanoic acid | 815618-98-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-6-bromo-5-oxo-2-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hexanoic acid
• CAS: 815618-98-5
• 化学式: C₂₃H₂₅BrN₂O₆
• 分子量: 505.365
• InChiKey: WODDCBZXZYKNAI-PMACEKPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  乙硫醚 、 (2S)-6-bromo-5-oxo-2-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hexanoic acid 以 甲醇 为溶剂， 反应 48.0h， 以85%的产率得到[5-[[2-(benzyloxycarbonylamino)-3-phenyl-propanoyl]amino]-6-hydroxy-2,6-dioxo-hexyl]-diethyl-sulfonium bromide
  参考文献：
  名称：

  Synthesis of potent water-soluble tissue transglutaminase inhibitors

  摘要：

  Dipeptide-based sulfonium peptidylmethylketones derived from 6-diazo-5-oxo-L-norleucine (DON) have been investigated as potential water-soluble inhibitors of extracellular transglutaminase. The lead compounds were prepared in four steps and exhibited potent activity against tissue transglutaminase. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.006
• 作为产物：
  描述：

  在 氢溴酸 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 生成 (2S)-6-bromo-5-oxo-2-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hexanoic acid
  参考文献：
  名称：

  Synthesis of potent water-soluble tissue transglutaminase inhibitors

  摘要：

  Dipeptide-based sulfonium peptidylmethylketones derived from 6-diazo-5-oxo-L-norleucine (DON) have been investigated as potential water-soluble inhibitors of extracellular transglutaminase. The lead compounds were prepared in four steps and exhibited potent activity against tissue transglutaminase. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.09.006

文献信息

• Imidazolium-based warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors
  作者：Eduard Badarau、Alexandre Mongeot、Russell Collighan、Dan Rathbone、Martin Griffin

  DOI：10.1016/j.ejmech.2013.05.018

  日期：2013.8

  New peptidic water-soluble inhibitors are reported. In addition to the carboxylate moiety, a new polar warhead was explored. Depending on the size of its substituents, the newly appended imidazolium scaffold designed to enhance the hydrophilic character of the inhibitors could induce a good inhibition for tissue transglutaminase (TG2) and blood coagulation factor XIIIa (EXIIIa). Correlated with the narrow tunnel that hosts the target catalytic cysteine residue, the various modulations suggest a bent conformation of the ligands as the binding pattern mode. Analogues in the dialkylsulfonium series were also tested and showed specificity for TG2 over FXIIIa. (c) 2013 Elsevier Masson SAS. All rights reserved.
• DIPEPTIDE TRANSGLUTAMINASE INHIBITORS AND METHODS OF USING THE SAME
  申请人：Aston University

  公开号：EP1648924B1

  公开（公告）日：2008-07-30
• Novel Compounds and Methods of Using the Same
  申请人：Griffin Martin

  公开号：US20080200511A1

  公开（公告）日：2008-08-21

  The present invention relates to novel compounds of Formula (I) wherein ‘X’ represents an amino acid group, ‘n’ is an integer between 1 and 4, ‘R 1 ’ represents benzyl, t-butyl or 9-fluorenylmethyl and ‘R 2 ’ represents a tetramethylmercaptoimidazole derivative or —S + R 3 R 4 , wherein R 3 and R 4 each independently represent lower alkyl, or a pharmaceutically and/or veterinarily acceptable derivative thereof. The present invention further relates to pharmaceutical formulations of said compound and the use thereof in the preparation of a medicament for inhibiting diseases in which transglutaminase has been implicated. Advantageously, the medicament is for treating fibrosis, scarring and/or cancer. Additionally, the invention relates to a method of inhibiting autoimmune diseases such as coeliac disease, neurodegeneration and chronic inflammatory diseases (e.g. of the joints including rheumatoid arthritis and osteoarthritis in a subject). The invention further relates to a method for preventing or treating rejection of a transplanted organ.
• US7723307B2
  申请人：——

  公开号：US7723307B2

  公开（公告）日：2010-05-25
• Synthesis of potent water-soluble tissue transglutaminase inhibitors
  作者：Martin Griffin、Alexandre Mongeot、Russell Collighan、Robert E. Saint、Richard A. Jones、Ian G.C. Coutts、Daniel L. Rathbone

  DOI：10.1016/j.bmcl.2008.09.006

  日期：2008.10

  Dipeptide-based sulfonium peptidylmethylketones derived from 6-diazo-5-oxo-L-norleucine (DON) have been investigated as potential water-soluble inhibitors of extracellular transglutaminase. The lead compounds were prepared in four steps and exhibited potent activity against tissue transglutaminase. (c) 2008 Elsevier Ltd. All rights reserved.